"10.1371_journal.pone.0148104","plos one","2016-02-05T00:00:00Z","Karin Neukam; José A Mira; Antonio Collado; Antonio Rivero-Juárez; Patricia Monje-Agudo; Josefa Ruiz-Morales; María José Ríos; Dolores Merino; Francisco Téllez; Inés Pérez-Camacho; María Carmen Gálvez-Contreras; Antonio Rivero; Juan A Pineda; HEPAVIR SEG-HEP-2007 Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)","Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain; Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain; Internal Medicine Service, Hospital Universitario de Valme, Seville, Spain; Internal Medicine Department, Hospital Torrecárdenas, Almeria, Spain; Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Maimonides Institute for Biomedical Research (IMIBIC), University of Cordoba, Cordoba, Spain; Unit of Infectious Diseases, Hospital Universitario Virgen de la Victoria, Malaga, Spain; Unit of Infectious Diseases, Hospital Universitario Virgen de la Macarena, Seville, Spain; Internal Medicine Service, Hospital Juan Ramón Jiménez. Huelva, Spain; Unit of Infectious Diseases, Hospital de La Línea de la Concepción, Cadiz, Spain; Unit of Tropical Medicine, Hospital Poniente, El Ejido, Spain","Conceived and designed the experiments: KN JAM JAP. Performed the experiments: KN JAM AC ARJ PMA JRM MJR DM FT IPC MCGC AR JAP. Analyzed the data: KN JAM JAP. Contributed reagents/materials/analysis tools: KN JAM AC ARJ PMA JRM MJR DM FT IPC MCGC AR JAP. Wrote the paper: KN JAM AC ARJ PMA JRM MJR DM FT IPC MCGC AR JAP.","K.N. has received lecture fees from Janssen-Cilag, Roche, Bristol-Meyers Squibb and Merck Sharp & Dohme and has received research support from Janssen-Cilag, Bristol-Meyers Squibb, Merck Sharp & Dohme, Gilead Sciences and Abbott Pharmaceuticals. A.R.J has received lecture fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, ViiV Healthcare and Roche. D.M. reports having received consultancy fees from Janssen Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, AbbVie and ViiH Healthcare. A.C. reports having received consultancy fees from Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, Pfizer and AbbVie. A.R. reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead Sciences, Merck Sharp & Dohme, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Boehringer Ingelheim and Schering-Plough. J.A.P. reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead Sciences, Merck Sharp & Dohme, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Boehringer Ingelheim and Schering-Plough. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2016","02","Karin Neukam","KN",14,TRUE,3,13,3,13,TRUE,TRUE,FALSE,0,NA,FALSE
